On February 2, 2024, the Department of Health and Human Services (HHS), through the Substance Abuse and Mental Health Services Administration (SAMHSA), published a final rule that expands on, and makes permanent, certain opioid-related telehealth flexibilities initiated during the COVID-19 pandemic. Under the rule, authorized providers will be able to start patients on buprenorphine or methadone—medications used to treat opioid use disorders—pursuant to a telehealth visit and without needing an in-person visit.
Read more »